Emine SÜTKEN, AYSEN AKALIN, FİLİZ ÖZDEMİR, Ömer ÇOLAK

Lipid profle and levels of homocysteine, leptin, fbrinogen and C-reactive protein in hyperthyroid patients before and after treatment

Amaç: Bu çalışma hipertiroidizmli hastalarda tiroid hormonlarının lipid proflini, eritrosit sedimentasyon hızını (ESR), serum total homosistein (t-hcy), leptin, fbrinojen ve C-reaktif protein (CRP) düzeylerini etkileyip etkilemediğini tespit etmek için tasarlanmıştır. Gereç ve yöntem: Bu çalışma yaş ortalaması 41.8±2.4 yıl arasında olan 23 hipertiroid (3 erkek/ 20 kadın) ile gerçekleştirildi. Homosistein, leptin, fbrinojen, CRP, total kolesterol (TK), yüksek dansiteli lipoprotein kolesterol (HDL-K), düşük dansiteli lipoprotein kolestrol (LDL-K)’ün serum düzeyleri ve ESR ölçüldü ve vücut kütle indeksi (BMI) tedaviden önce ve sonra hesaplandı. Bulgular: Hipertiroid hastalarının tedavi öncesi t-hcy, TC, LDL-Kolesterol, HDL-Kolesterol düzeyleri ve BMI tedavi sonrası düzeylerden daha düşüktü (tüm değişkenler için, p

Hipertiroid hastalarda tedavi öncesi ve sonrası lipid profli ile homosistein, leptin, fbrinojen ve C-reaktif protein düzeyleri

Objectives: The present study was carried out to determine whether thyroid hormones affect lipid profle and levels of erithrocyte sedimentation rate (ESR), serum total homocysteine (t-hcy), leptin, fbrinogen, C-reactive protein (CRP in patients with hyperthyroidism. Materials and methods: This study was carried out on 23 hyperthroid subjects (3 men / 20 women, mean age 41.8 ± 2.4 years). Serum levels of homocysteine, leptin, fbrinogen, CRP, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and ESR were measured and body mass index (BMI) were calculated before and after treatment of hyperthyroidism. Results: Pretreatment t-hcy, TC, LDL-C, HDL-C levels and BMI of patients were signifcantly lower than those of the post-treatment (p<0.001, for each variable). However, fbrinogen and ESR decreased after the treatment (p<0.001 and p<0.05, respectively). There were no differences in leptin and CRP levels between pre- and posttreatment periods. Pre and post treatment TC and LDL-C levels were negatively correlated with free triiodothyronine (fT3) levels (r=-0.588, p<0.01; r=-0.534, p<0.01; r=-0.543, p<0.01 and r =-0.653, p<0.01, respectively). Pre-treatment HDL-C was inversely correlated with TSH (r=-0.423, p<0.05). Pre-post- treatment LDL-C was negatively correlated with free thyroxine (fT4) levels (r=-0.536, p<0.001 and r=- 0.422, p<0.05 respectively). Pre-treatment TC was inversely correlated with fT4 (r=-0.590, p<0.01). Conclusion: Hyperthyroidism is associated with high plasma fbrinogen and ESR levels. Elevated plasma fbrinogen and ESR levels may be a possible explanation for the high cardiovascular morbidity among hyperthyroidic subjects. These changes may refect low-gradeinfammation or disturbances in coagulation in hyperthyroidism.

PDF

___

1. Faber J, Wiinberg N, Schifter S, Mehlsen J. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol 2001;145:391-396.
2. Diekman MJ, Anghelescu N, Endert E, Bakker O, Wiersinga WM. Changes in plasma low-density lipoprotein (LDL) - and high-density lipoprotein cholesterol in hypo- and hyperthyroid patients are related to changes in free thyroxine, not to polymorphisms in LDL receptor or cholesterol ester transfer protein genes. J Clin Endocrinol Metab 2000;85:1857-1862.
3. Wonn-Young L, Jung-Yul S, Eun-Jung R, Jeong-Sik P, KiChul S, Sun-Woo K. Plasma CRP, Apolipoprotein A-1, Apolipoprotein B and Lp (a) levels according to thyroid function status. Arch Med Res 2004;35:540-545.
4. Chadarevian R, Bruckert E, Giral P, Turpin G. Relationship between thyroid hormones and fbrinogen levels. Blood Coagul Fibrinolysis 1999;10:481-486.
5. Diekman MJ, van der Put NM, Blom HJ, Tijssen JG, Wiersinga WM. Determinants of changes in plasma homocysteine in hyperthyroidism and hypothyroidism. Clin Endocrinol (Oxf) 2001;54:197-204.
6. Matsubara M, Yoshizawa T, Morioka T, Katayose S. Serum leptin and lipids in patients with thyroid dysfunction. J Atheroscler Thromb 2000;7:50-54.
7. Hofbauer LC, Heufelder AE. Coagulation disorders in thyroid diseases. Eur J Endocrinol 1997;136:1-7.
8. Yarnell JW, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991;83:836-844.
9. Rosengren A, Wilhelmsen L, Welin L, Tsipogianni A, TegerNilsson AC, Wedel H. Social infuences and cardiovascular risk factors as determinants of plasma fbrinogen concentration in a general population sample of middle aged men. BMJ 1990;10300(6725): 634-638.
10. Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fbrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991;91:191-205.
11. Takeda I, Kometani T. Emergency laboratory service in Shimane Prefectural Central Hospital (author’s transl) Rinsho Byori 1981;29:37-41.
12. Thompson SG, Fechtrup C, Squire E, et al. Antithrombin III and fbrinogen as predictors of cardiac events in patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996;16:357-362.
13. Anderson JL, Carlquist JF, Muhlestein JB, Horne BD, Elmer SP. Evaluation of C-reactive protein, an infammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol 1998;32:35-41.
14. Mendall MA, Patel P, Ballam L, Strachan D, Northfeld TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312(7038):1061-1065.
15. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-1050.
16. Catargi B, Parrot-Roulaud F, Cochet C, Ducassou D, Roger P, Tabarin A. Homocysteine, hypothyroidism, and effect of thyroid hormone replacement. Thyroid 1999;9:1163-1166.
17. Barbe F, Klein M, Chango A, et al. Homocysteine, folate, vitamin B12, and transcobalamins in patients undergoing successive hypo- and hyperthyroid states. J Clin Endocrinol Metab 2001; 86:1845-1846.
18. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefts of increasing folic acid intakes. JAMA 1995;274:1049-1057.
19. Brattstrom L, Israelsson B, Tengborn L, Hultberg B. Homocysteine, factor VII and antithrombin III in subjects with different gene dosage for cystathionine beta-synthase. J Inherit Metab Dis 1989;12:475-482.
20. Leonhardt U, Ritzel U, Schafer G, Becker W, Ramadori G. Serum leptin levels in hypo- and hyperthyroidism. J Endocrinol 1998;157:75-79.
21. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269(5223):543-546
22. Papaspyrou-Rao S, Schneider SH, Petersen RN, Fried SK. Dexamethasone increases leptin expression in humans in vivo. J Clin Endocrinol Metab 1997;82:1635-1637.
23. Cusin I, Sainsbury A, Doyle P, Rohner-Jeanrenaud F, Jeanrenaud B. The ob gene and insulin. A relationship leading to clues to the understanding of obesity. Diabetes 1995;44:1467-1470.
24. Corbetta S, Englaro P, Giambona S, Persani L, Blum WF, Beck-Peccoz P. Lack of effects of circulating thyroid hormone levels on serum leptin concentrations. Eur J Endocrinol 1997;137:659-663.
25. Oge A, Bayraktar F, Saygili F, Guney E, Demir S. TSH infuences serum leptin levels independent of thyroid hormones in hypothyroid and hyperthyroid patients. Endocr J 2005;52:213-217.
26. Nedrebo BG, Ericsson UB, Nygard O, et al. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism 1998;47:89-93.
27. Nygard O, Vollset SE, Refsum H, Brattstrom L, Ueland PM. Total homocysteine and cardiovascular disease. J Intern Med 1999; 246: 425-454.
28. Demirbas B, Ozkaya M, Cakal E, et al. Plasma homocysteine levels in hyperthyroid patients. Endocr J 2004; 51: 121-125.
29. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic infuence of increased fbrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997;96:4204-4210.
30. Pasceri V, Willerson JT, Yeh ET. Direct proinfammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168.
31. Burggraaf J, Lalezari S, Emeis JJ, et al. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid 2001; 11: 153-160.
32. Erem C, Ersoz HO, Karti SS, et al. Blood coagulation and fbrinolysis in patients with hyperthyroidism. J Endocrinol Invest 2002; 25: 345-350.
33. Horne MK 3rd, Singh KK, Rosenfeld KG, et al. Is thyroid hormone suppression therapy prothrombotic? J Clin Endocrinol Metab 2004; 89: 4469-4473.
34. Lin KH, Lee HY, Shih CH, et al. Plasma protein regulation by thyroid hormone. J Endocrinol 2003; 179: 367-377.
35. Shih CH, Chen SL, Yen CC, et al. Thyroid hormone receptor-dependent transcriptional regulation of fbrinogen and coagulation proteins. Endocrinology 2004;145:2804-2814.
36. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10 year cohort study. Lancet 2001;358(9285):861-865.
37. Engler H, Riesen WF. Effect of thyroid function on concentrations of lipoprotein(a). Clin Chem 1993;39:2466-2469.
38. Ponsin G, Vialle-Valentin C, Berthezene F. Alterations of high density lipoproteins induced by thyroid hormones in man and rat. Adv Exp Med Biol 1991;285:147-154.
39. Ruggiero FM, Cafagna F, Quagliariello E. Exchange of free cholesterol between plasma and erythrocytes from hyperthyroid and hypothyroid rats in vitro.Lipids 1990;25:529-533.
40. Staels B, Van Tol A, Chan L, Will H, Verhoeven G, Auwerx J. Alterations in thyroid status modulate apolipoprotein, hepatic triglyceride lipase, and low density lipoprotein receptor in rats. Endocrinology 1990;127:1144-1152.
41. Hoch FL. Lipids and thyroid hormones. Prog Lipid Res 1988;27:199-270.
42. Yoshida T, Momotani N, Hayashi M, Monkawa T, Ito K, Saruta T. Serum leptin concentrations in patients with thyroid disorders. Clin Endocrinol (Oxf) 1998;48:299-302.
43. Zimmermann-Belsing T, Dreyer M, Holst JJ, Feldt-Rasmussen U. The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects. Clin Endocrinol (Oxf) 1998;49:589-595.
44. Iglesias P, Alvarez Fidalgo P, Codoceo R, Diez JJ. Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. Clin Endocrinol (Oxf) 2003;59:621-629.
45. Pinkney JH, Goodrick SJ, Katz J, et al. Leptin and the pituitary-thyroid axis: a comparative study in lean, obese, hypothyroid and hyperthyroid subjects. Clin Endocrinol (Oxf) 1998;49:583-588.
46. Sesmilo G, Casamitjana R, Halperin I, Gomis R, Vilardell E. Role of thyroid hormones on serum leptin levels. Eur J Endocrinol 1998;139:428-430.